oxy update out - stay tuned, page-81

Dear All,

I hate to rain on the parade of those impending doom, but they can run the two trials concurrently and I suspect that may be the plan. In fact adding two more control arms will deliver end points that give value to each other for very little extra cost, ie humans. The cost is always in the protocols at this level not the quantum. There are economies of scale when looking at this for the same outcome ie pain. And it provides a fall back position unlike others that have led with a one cure fits all strategy and failed recently ie Qrx

I think you will find they have a much bigger plan in place than these two actives, I think it is a portfolio of pain products for a platform technology

My instinct is that the sp will now rise to dec 2011 levels once the market understands the significance which means I lose the Jacobs Creek.

BSW